openPR Logo
Press release

BellaSeno Establishes GMP-Compliant High-Throughput Additive Manufacturing Facility for Resorbable Medical Implants

11-17-2020 04:02 PM CET | Health & Medicine

Press release from: BellaSeno GmbH

/ PR Agency: akampion
- Seamless transition from R&D to commercial-scale additive manufacturing
- Leading-edge cleanroom, no-touch manufacturing
- GMP capabilities for internal and contract manufacturing

Leipzig, Germany, November 17, 2020 - BellaSeno GmbH, an ISO 13485-certified medtech company developing absorbable scaffolds using additive manufacturing technologies, today announced the establishment of a novel, leading-edge additive manufacturing facility for medical implants supported by the Fraunhofer Institute for Cell Therapy and Immunology IZI, Leipzig, Germany.

It is the one of the first GMP-compliant manufacturing facilities worldwide to include innovative features such as high-througput additive manufacturing based on the so-called no-touch approach to significantly improve the safety and sterility of medical implants. Moreover, the facility allows for a seamless transition from R&D to commercial-scale manufacturing and provides capabilities for both internal and contract manufacturing.

While BellaSeno contributed its additive manufacturing expertise, Fraunhofer IZI was responsible for developing GMP-compliant processes, quality assurance and quality control. The resulting infrastructure, incl. SOPs and documentation, was then certified and transferred to BellaSeno.

“We are delighted to have established a truly unique additive manufacturing facility together with Fraunhofer IZI,” said Mohit Chhaya, PhD, Chief Executive Officer of BellaSeno. "This will not only ensure leading-edge manufacturing of our own products, but also enables us to provide contract manufacturing of resorbable medical implants for a wide range of applications."

He added that BellaSeno is the one of the first European companies with an ISO13485 certification covering the entire additive design and manufacturing process. Moreover, the Company is able to reproducibly and routinely manufacture scaffolds with feature sizes down to 150-µm - an important differentiation factor in the additive manufacturing sector.

“We are very glad to have developed a strong foundation of GMP-level production processes over the last three years in close collaboration with the Fraunhofer IZI team," said Arpita Desai, M.E., Head of Quality Management at BellaSeno. “The exchange of knowledge throughout the project will allow us to produce implants in our new ISO 14644 Class 7 cleanroom facility at a much higher quality compared to current standards – leading to safer patient outcomes."


Contact BellaSeno
BellaSeno GmbH
Deutscher Platz 5a (BioCity)
04103 Leipzig
Dr. Mohit Chhaya
mohit.chhaya@bellaseno. com
Tel.: +49 176 2283 9583

Media Inquiries
Dr. Ludger Wess / Ines-Regina Buth
Managing Partners
Tel. +49 40 88 16 59 64
Tel. +49 30 23 63 27 68

Contact Fraunhofer IZI
Jens Augustin
Head of Press and Public Affairs
Fraunhofer Institute for Cell Therapy and Immunology
Perlickstraße 1
04103 Leipzig, Germany
Tel. +49 341 35536-9320

About BellaSeno
BellaSeno GmbH was founded in 2015 and is located on the BioCity campus in Leipzig, Germany. The Company is developing novel absorbable soft tissue reconstruction implants made by additive manufacturing (3D-printing) under ISO 13485 certification. The Company has received substantial financial support from private investors as well as from the Saxony Development Bank (SAB) and the European Fund for Regional Development (EFRE). The Company is thereby co-funded from tax resources based on the budget adopted by the members of Saxon State Parliament.

About Senella®
Senella® is a patented porous scaffold made of absorbable Polycaprolactone (PCL) containing highly-specialized topological and design features, which act as recipients for injected fat tissue isolated with a standard liposuction procedure. The implant is designed to get absorbed over a span of two years and to provide a stable platform for the injected fat tissue to mature, adapt to its environment and stabilize. The clinical end result is a natural soft tissue – without remnants of foreign material. Senella® therefore has the potential to alleviate the complications found in current breast reconstruction and augmentation approaches.

About the Fraunhofer Institute for Cell Therapy and Immunology IZI
The Fraunhofer Institute for Cell Therapy and Immunology IZI investigates and develops solutions to specific problems at the interfaces of medicine, life sciences and engineering. One of the institute‘s main tasks is to conduct contract research for companies, hospitals, diagnostic laboratories and research institutes operating in the field of biotechnology, pharma¬ceuticals and medical engineering.
The Fraunhofer IZI develops, optimizes and validates methods, materials and products for the business units Cell and Gene Therapy, Drugs and Diagnostics. Its areas of competence lie in cell biology, immunology, drug biochemistry, bioanalytics and bioproduction as well as process development and automation. In these areas, research specifically focusses on the indications oncology, immunological diseases as well as infectious diseases and neurodegenerative diseases.
The institute works in close cooperation with hospital institutions and performs quality tests besides carrying out the GMP-compliant manufacture of clinical test samples. Furthermore, it helps partners obtain manufacturing licenses and permits.

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release BellaSeno Establishes GMP-Compliant High-Throughput Additive Manufacturing Facility for Resorbable Medical Implants here

News-ID: 2188655 • Views: 474

More Releases from BellaSeno GmbH

BellaSeno Initiates Scaffold Development Program for Tendon and Ligament Regener …
- Collaboration with Fraunhofer IZI further expanded - Funding provided by Sächsische Aufbaubank Leipzig, Germany, July 1, 2021 – BellaSeno GmbH, an ISO 13485-certified medtech company developing absorbable scaffolds using additive manufacturing technologies, today announced that the Company has initiated a program on tendon and ligament reconstruction funded by the State of Saxony´s Sächsische Aufbaubank (SAB). The program will be run in close collaboration with Fraunhofer Institute for Cell Therapy and Immunology
BellaSeno Wins Prestigious German Innovation Award 2021
- Leading-edge Senella® soft tissue technology awarded for excellence in B2B / medical technologies Leipzig, Germany, May 18, 2021 – BellaSeno GmbH, an ISO 13485-certified medtech company developing absorbable scaffolds using additive manufacturing technologies, today announced that the Company has received the German Innovation Award from the German Design Council for its Senella® technology in the category #W2 Excellence in Business to Business - Medical Technologies. BellaSeno has been chosen among
BellaSeno and Charite - Universitaetsmedizin Berlin Collaborate Under BMBF-Funde …
- Development of absorbable implants for the personalized treatment of bone defects in patients with diabetes - BellaSeno responsible for high resolution, medical-grade scaffold manufacturing under ISO 13485 Leipzig, Germany, March 24, 2020 - BellaSeno GmbH, a company developing absorbable scaffolds using additive manufacturing technologies, today announced a collaboration with Charite - Universitaetsmedizin Berlin under the recently established SyMBoD consortium. Under the agreement, BellaSeno will design and manufacture personalized, 3D-printed, absorbable
Evonik and BellaSeno partner to enable the launch of an innovative 3D printed br …
- 3D printed breast scaffolds to be made of RESOMER® - Degradation of RESOMER® to match the growth of the patient’s own tissue for natural breasts - Technology designed to improve quality of life for patients after breast reconstruction and augmentation - Human clinical trials to commence later this year Evonik, a global leader in biomaterials for implantable medical devices, and BellaSeno GmbH, a developer of 3D printed absorbable scaffolds, today announced the signing

All 5 Releases

More Releases for Fraunhofer

Fraunhofer IAO joins “Partnership on AI“
Working together to increase the benefits of artificial intelligence for people and the workplace Founded by big tech companies such as Apple, IBM and Microsoft, the Partnership on AI promotes collaboration and exchange on the important topic of artificial intelligence. Through its membership, Fraunhofer IAO is playing an active part in developing AI best practices and technologies to benefit businesses and society. “Over the next few years, applications based on artificial intelligence
Fraunhofer award for smart scooter
“ElectromobileCityScooter” sustainable urban distribution solution receives German High Tech Champions Award On April 3, 2014 in Paris, the Fraunhofer-Gesellschaft will honor Fraunhofer IAO’s Daniel Borrmann as German High Tech Champion in the Urban Distribution category for his pioneering technological development, the “ElectromobileCityScooter.” This nimble, electrically driven three-wheel microcar won over the jury as a sustainable solution for the urban distribution sector and will also be making an appearance at the Hannover
Fraunhofer IAO launches "Kopfarbeit Index KAI"
What constitutes attractive work for students and our high-potential employees? How do the students of today want to work tomorrow? Fraunhofer IAO has been using its “Kopfarbeit-Index KAI®” to find out. Since September, students have been invited to define their ideal working conditions by completing an online questionnaire. By joining the KAI working group, companies can find out exactly what their top performers value most at work, and discover which working
Change in leadership at Fraunhofer IAO
Wilhelm Bauer to succeed Dieter Spath on October 1 Prof. Dr. Dieter Spath, long-standing director of Fraunhofer IAO and of the IAT at the University of Stuttgart, will become chairman of the Management Board for the WITTENSTEIN Group on October 1, 2013. Prof. Dr. Wilhelm Bauer, previously deputy director, will take over as acting director of both institutes. Apl. Prof. Dr. Anette Weisbecker will assume the role of deputy director. After
arvato Systems Cooperates with Fraunhofer IML
Announcement at LogiMAT on warehouse management cooperation arvato Systems, Gütersloh/Stuttgart, Germany, 13 March 2012 – Systems integrator arvato Systems and the Fraunhofer Institute for Material Flow and Logistics IML have now begun cooperating even closer with each other in the area of warehouse management systems, or WMS for short. An intensive exchange of experiences and participation by arvato Systems in the objective WMS evaluation platform ‘warehouse logistics,’ which has been initiated
Fraunhofer FOKUS at CeBIT 2012
„Urban Living“ is the motto of the Fraunhofer-Gesellschaft at this years’ CeBIT tradeshow in Hannover. From March 6 – 10, the Fraunhofer Institute FOKUS will be showing different sorts of innovations concerning the smart city of the future. Berlin, March 2012 – This year Fraunhofer FOKUS is showing how innovative IT is changing life in urban areas. The main topics are: Electromobility – Smartly Connected How traffic management works in the city of